Effect of Hypoglycemia on Sleep
NCT02687893 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2019-04-10
Summary
Growing evidence provided by many observational studies has established a strong link between decreased sleep duration and poor glucoregulation. Sleep deprivation and poor sleep quality induce insulin resistance and decrease glucose tolerance in healthy individuals. However, the influence of poor sleep quality on glycemic control of patients with Type 1 diabetes mellitus (T1DM) is unknown. Persistent sleep deprivation among patients with T1DM has been reported, and this sleep loss can be attributed in part to nocturnal hypoglycemia. Nocturnal iatrogenic hypoglycemia is a limitation of current intensive insulin therapies. Although severe hypoglycemia is associated with adverse events such as seizures and death, less severe nocturnal hypoglycemia has been linked to broad range of adverse consequences, both acutely and long term. Hypoglycemia stimulates the sympathetic nervous system as a stress response, leading to the stimulation of the hypothalamic-pituitary-adrenal axis (HPA). This results in a counter regulatory hormone cascade, which elicits an excessive cortisol secretion, which is known to cause sleep disturbance and could impair glucose homeostasis after the hypoglycemic event. The hyperinsulinemia in T1DM patients promotes HPA hyperactivity as well, which is also associated with impaired sleep quality by leading to sleep fragmentation, decreased slow wave sleep and shortened sleep duration. Sleep disturbances due to nocturnal hypoglycemia can exacerbate HPA axis dysfunction, adversely affecting the sleep-wake cycle.
The goal of the study is to understand the impact of nocturnal hypoglycemia on sleep.
Conditions
Interventions
- BEHAVIORAL
-
Aerobic Exercise
Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
- BEHAVIORAL
-
Resistance Exercise
Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
Sponsors & Collaborators
-
Oregon Health and Science University
lead OTHER
Principal Investigators
-
Peter G Jacobs, PhD · Oregon Health and Science University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-29
- Primary Completion
- 2016-09-30
- Completion
- 2018-07-18
Countries
- United States
Study Locations
More Related Trials
-
Exercise-induced Glycemic Variations and Hybrid Closed-loop Systems
NCT05736263 ·Status: UNKNOWN ·Phase: NA
-
Naloxone, Hypoglycemia and Exercise
NCT03149770 ·Status: COMPLETED ·Phase: PHASE2
-
Cerebral Responses to Insulin Induced Hypoglycemia
NCT02747680 ·Status: COMPLETED ·Phase: NA
-
Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes
NCT02866435 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Sympathetic Nerve Activity During Hypoglycemia and Exercise
NCT00608348 ·Status: COMPLETED ·Phase: NA
-
Effect of C-peptide on Hypoglycemic Counterregulation
NCT06470295 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
HIT on Hypoglycaemic Risk in T1D
NCT05044442 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3
NCT00742521 ·Status: COMPLETED ·Phase: NA
-
Consequences of Hypoglycemia on Intensive Care Unit (ICU) Patients
NCT00662922 ·Status: COMPLETED
-
Hypoglycemia: Physician and Patient Perspectives
NCT01176656 ·Status: COMPLETED
-
The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow
NCT02146404 ·Status: COMPLETED ·Phase: NA
-
Naltrexone and Hypoglycemia in Type 1 Diabetes
NCT01053078 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens
NCT02758522 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia
NCT00600730 ·Status: WITHDRAWN ·Phase: NA
-
Prevention of Mild-to-moderate Hypoglycemia in Type 1 Diabetes
NCT04876079 ·Status: COMPLETED ·Phase: NA
-
Avoidance of Hyperglycaemia in People With Type 1 Diabetes
NCT04732780 ·Status: COMPLETED
-
Rebreathing-induced Hypoxia and Glucose Levels
NCT05422430 ·Status: COMPLETED ·Phase: NA
-
Hypoglycemia in Hospitalized Patients
NCT02228642 ·Status: COMPLETED
-
Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1
NCT00655460 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring
NCT01714895 ·Status: COMPLETED ·Phase: NA
-
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
NCT00993057 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
NCT01462227 ·Status: COMPLETED ·Phase: NA
-
Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia
NCT03214107 ·Status: COMPLETED ·Phase: NA
-
Intensive Glycemic Management and Outcomes Following Liver Transplantation
NCT01432093 ·Status: COMPLETED ·Phase: NA
-
In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome
NCT00302874 ·Status: COMPLETED ·Phase: NA